More on President’s request for an FDA BA of $3.653 Billion Total; Volunteers Sought for Hill Meetings April 20/21 and beyond
Top-Line:
Analysis and Commentary: Summary of Remarks by FDA Leaders
Alliance Supports Administration Call for $336 Million More in BA/ $3.653 Billion Total
Volunteers Sought for Hill Meetings on April 20, 21 and beyond
Hear FDA Leaders Discuss FY 23 Budget Priorities in our Alliance Webinar Series
Why Sign-up to Listen to CVM Director Dr. Steven Solomon (April 22)?
Interested in Previous Alliance Webinars? Transcript and Recordings
This week’s Analysis and Commentary summarizes the comments of:
Associate Commissioner for Regulatory Affairs Judy McMeekin on April 6, 2022, [transcript][video]
CFSAN Director Dr. Susan Mayne on April 12, 2022 [video]
during their appearances at Alliance webinars. The transcript and summary of our webinar with Dr. Cavazzoni was in last week’s Analysis and Commentary.
Alliance Establishes FY 23 “Ask”; Supports $336 Million Increase for FDA. The Alliance for a Stronger FDA supports the Administration’s BA request of $3.653 billion. This provides for an increase of $318 million in BA salary and expenses (S&E) and an increase of $18 million in BA buildings and facilities (B&F). We also support the proposed no-year money requests for pandemic response ($1.6 billion) and the Cancer Moonshot ($20 million).
More details on the Alliance's position and analysis of the President’s Budget Request can be found here.
Note that we are still in the process of reviewing the Administration’s detailed budget request to provide additional information about the strengths of the request and any areas in which we think additional emphasis is needed.
Alliance Campaign Encourages Members of Congress to Request Increased FDA Funding. During March and April of each year, Members of Congress ask their constituents and interested parties to recommend program funding for the coming fiscal year. In turn, Members formulate a list of their priorities, which they share with subcommittee leadership. We are encouraging Members to ask for increased FDA funding as part of their priority list.
For this purpose, we are scheduling two Hill Days (House and Senate) for April 20 and 21. There are still open slots for those days, so if you would like to participate, please contact Elisa Bayoumi
Even if you cannot participate on April 20 and 21, stay tuned for more opportunities to participate at subsequent Hill Days.
Hear FDA Leaders Discuss FY 23 Budget Priorities in our Alliance Webinar. Hear FDA leaders discuss their FY 23 budget priorities as part of this exclusive Alliance webinar series.
Steven Solomon, DVM | CVM | April 22, 3 p.m. | Register
Jeff Shuren, MD | CDRH | April 29, 11 a.m. | Register
Peter Marks, MD | CBER | May 10, 1 p.m. | Register
These online events are for Alliance members and media, although we welcome guests. If you are not an Alliance member and would like to participate, please contact Alliance Executive Director, Steven Grossman.
Why Sign-Up to Listen to Dr. Solomon? CVM contributes to human and animal health by ensuring:
the safety of the American food supply;
the safety of animal food and devices; and
the safety and effectiveness of animal drugs.
The Center’s scope is large, encompassing companion (pet) animals, such as dogs, cats, and horses; and food-producing animals, such as cattle, pigs, chickens, and even honeybees. If an animal drug is for a food-producing animal, before approving it, the Center also must make sure that food products made from treated animals—meat, milk, eggs, and honey—are safe for people to eat.
We take it for granted that pets often depend on full nutrition from a single formulation of pet food and that we rely on many products derived from animals. CVM is the lead FDA agency for addressing antibiotic resistance. We are also hoping Dr. Solomon will address a question or two about zoonotic disease and the challenges it poses for human health.
Five Alliance Webinars Completed this Year. We have audio and, in most cases, transcripts of the five Alliance webinars this year. They cover the FDA Office of Chief Scientist, How FDA is Funded, CDER, the Office of Regulatory Affairs, and CFSAN. If you are interested, contact Elisa Bayoumi.